SK Bioscience announced on the 19th that it has applied for a Phase 3 clinical trial in Europe for the 21-valent pneumococcal vaccine jointly developed with Sanofi.
On the 18th (local time), SK Bioscience submitted the clinical trial plan through the European Medicines Agency (EMA) Clinical Trial Information System (CTIS).
This clinical trial, involving approximately 1,080 participants, aims to prevent pneumococcal diseases caused by pneumococcus in infants, children, and adolescents.
SK Bioscience explained, "Approval of the clinical trial will be determined after review by each member country (regulatory authorities and ethics committees) where the trial is conducted."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
